MYB and acute myeloid leukemia: In AML, upregulated m6A modification on MYB, MYC, BCL2, PTEN and SP1 results in enhancement of the binding capability and translational efficiency of onco-RNA and ribosomes, leading to tumorigenesis [47–50].